The Melbourne-based healthcare AI company is making waves around the world.
Melbourne-based AI company Heidi has raised A$120 million in Series B funding to accelerate the rollout of its AI Care Partner, a platform designed to reduce administrative workload for clinicians.
Led by Point72 Private Investments with continued support from Blackbird, Headline, and Latitude, Phoenix Court’s growth fund, the round values Heidi at A$860 million and brings total funding to nearly A$185 million.
In the same statement, the company also made two new key executive appointments, including internationally recognised digital health leader Dr Simon Kos as chief medical officer. Dr Kos was formerly CMO at Microsoft and described Heidi’s vision as “bold”.
“With Heidi by their side, clinicians not only improve their experience of delivering care but the patients’ experience of receiving it,” Dr Kos said.
“Heidi’s bold vision extends beyond the current promise of ambient voice technology and into a future where every clinician can leverage AI to expand their clinical capacity while protecting the human touch in healthcare.”
Heidi has also appointed Paul Williamson as chief revenue officer. Mr Williamson was formerly the head of revenue at Plaid.
Mr Williamson was also keen to get on board.
“During my career, I’ve chosen to work with companies that have transformed their respective industries – from Salesforce in customer relationship management to Plaid in financial services,” he said.
“Today, I join Heidi’s mission to redefine healthcare in the age of AI.”
Heidi is now the fastest-growing company in Blackbird’s portfolio (by revenue), surpassing Australian multinational proprietary software company Canva.
The Series B funding will accelerate Heidi’s mission to build an AI Care Partner that sits alongside clinicians, expanding their capacity by automating tasks such as clinical documentation, evidence search, and follow-up communications.
It will also allow Heidi to continue to expand its headcount, office locations and local support in the USA, UK and Canadian markets and build on clinician-led adoption in France, Spain, Germany, Ireland, South Africa, Singapore and Hong Kong.
In the UK, Heidi powers Modality Partnership’s largest ambient AI deployment and supports pilot programs with NHS Trusts in North West London and Lancashire and South Cumbria.
In the USA, it is used by Beth Israel Lahey Health in Massachusetts and MaineGeneral in Maine.
In Canada, it has been selected by the Yukon Government, while in Australia it supports Monash Health and Queensland Health Children’s Hospital and Health Service. New Zealand’s Health Ministry has formally endorsed Heidi as one of two AI providers safe for public health system trials.
Michael Tolo, a partner at Blackbird, said Heidi stood out for its “tangible and meaningful impact”.
“Heidi is saving clinicians over an hour each day and supporting more than 2m consults a week, which alone gives the company line of sight to increase the capacity of our healthcare system by 10%,” he said.
Related
“This growth has excitingly been driven by the hard-working doctors Heidi exists to support, who have fallen in love with the product and championed it to the global stage.”
Latitude partner Ferdi Sigona agreed.
“What we’re witnessing with Heidi in the UK’s NHS isn’t just fast growth, it’s a clinician-led movement,” he said.
“When doctors themselves are championing a tool so passionately – from individual practices to major NHS Trusts serving millions of patients – you know we’re backing a company with universal appeal across healthcare.
“We’re thrilled to be doubling down on Heidi alongside new and existing investors, and are convinced the team’s success so far is only the beginning.”
Heidi’s AI platform automates tasks such as clinical documentation, evidence searches, and follow-up communications tasks that it says consume nearly as much clinician time as direct patient care.
In just 18 months, Heidi says it has freed up more than 18 million hours for frontline clinicians, helping health systems worldwide tackle burnout and capacity pressures.
Tens of thousands of clinicians across more than 200 specialties now use Heidi’s technology. The platform has supported 73 million patient consults and currently manages over two million weekly consults in 110 languages across 116 countries.
Dr Thomas Kelly, Heidi’s CEO and co-founder, and former vascular surgical resident, said it was “untenable that healthcare demand continues to rise while clinical time continues to shrink”.
“Building a sustainable healthcare system requires expanding clinical capacity without compromising clinician wellbeing or patient safety,” he said.
“That’s why I founded Heidi: to build an AI Care Partner that stands alongside clinicians, empowering them to deliver the care to which they have dedicated their lives.”
Sri Chandrasekar, managing partner at Point72 Private Investments, which led the Series B funding round, shared his confidence in Heidi’s future.
“We believe administrative burden is contributing to clinician burnout and capacity challenges across healthcare systems,” said Mr Chandrasekar.
“Heidi’s platform has the potential to meaningfully improve how clinicians manage their administrative workflows.
“We’re impressed by the adoption rates they’ve demonstrated within health systems and are excited to support their vision of expanding healthcare capacity while preserving the human touch in patient care.”